ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs

Chen, Geng-Hang; Liu, Zhiwei; Yu, Kelly J.; Coghill, Anna E.; Chen, Xiao-Xia; Xie, Shang-Hang; Lin, Dong-Feng; Huang, Qi-Hong; Lu, Yu-Qiang; Ling, Wei; Lin, Chu-Yang; Lu, Zi-Jian; Fan, Yu-Ying; Tang, Lin-Quan; Sampson, Joshua N.; Li, Hui; King, Ann D.; Middeldorp, Jaap M.; Hildesheim, Allan*; Cao, Su-Mei*广东省人民医院; 广州中医药大学; 中山大学; 6
Clinical Chemistry2022-7-3DOI: 10.1093/clinchem/hvac032
6被引5阅读
引用收藏
分享

摘要

Background Epstein-Barr virus (EBV) DNA detection in the nasopharynx is considered a biomarker for nasopharyngeal carcinoma (NPC). We evaluated its performance as a reflex test to triage EBV seropositives within an NPC screening program in China. Methods The study population was embedded within an ongoing NPC screening trial and included 1111 participants who screened positive for anti-EBV VCA (antibodies against EBV capsid antigens)/EBNA1 (EBV nuclear antigen1)-IgA antibodies (of 18 237 screened). Nasopharynx swabs were collected/tested for EBNA1 gene EBV DNA load. We evaluated performance of EBV DNA in the nasopharynx swab as a reflex test to triage EBV serological high-risk (those referred to endoscopy/MRI) and medium-risk (those referred to accelerated screening) individuals. Results By the end of 2019, we detected 20 NPC cases from 317 serological high-risk individuals and 4 NPC cases from 794 medium-risk individuals. When used to triage serological high-risk individuals, nasopharynx swab EBV DNA was detected in 19/20 cases (positivity rate among cases: 95.0%; 95% CI, 75.1%-99.9%), with a referral rate of 63.4% (201/317, 95% CI, 57.8%-68.7%) and NPC detection rate among positives of 9.5% (19/201, 95% CI, 5.8%-14.4%). The performance of an algorithm that combined serology with triage of serology high-risk individuals using EBV DNA testing yielded a sensitivity of 72.4% (95% CI, 3.0%-81.4%) and specificity of 97.6% (95% CI, 97.2%-97.9%). When used to triage EBV serological medium-risk individuals, the positivity rate among cases was 75.0% (95% CI, 19.4%-99.4%), with a referral rate of 61.8% (95% CI, 58.4%-65.2%) and NPC detection rate among positives of 0.6% (95% CI, 0.1%-1.8%). Conclusions Nasopharynx swab EBV DNA showed promise as a reflex test to triage serology high-risk individuals, reducing referral by ca. 40% with little reduction in sensitivity compared to a serology-only screening program.

学科与关键词

关键词
cancermolecular diagnosticsepidemiology studies
相关
加载中…
  • Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer.
    Chan K C Allen; Woo John K S; King Ann; Zee Benny C Y; Lam W K Jacky; Chan Stephen L; Chu Sam W I; Mak Constance; Tse Irene O L; Leung Samantha Y M; Chan Gloria; Hui Edwin P; Ma Brigette B Y; Chiu Rossa W K; Leung Sing Fai; van Hasselt Andrew C; Chan Anthony T C; Lo Y M DennisN Engl J Med, 2017, 377(6): 513-522.
  • [The value of plasma EBV-DNA testing in high-risk group of nasopharyngeal carcinoma in the nasal endoscopy].
    He X F; Yu X; Ji M F; Fu M YLin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, 2017, 31(10): 770-773.
  • Clinical relevance of plasma EBV DNA as a biomarker for nasopharyngeal carcinoma in non-endemic areas: A multicenter study in southwestern China
    He, Qiao; Zhou, Yi; Zhou, Jie; Zhao, Dan; Li, Luona; Li, Xianbing; Huang, Yecai; Wang, Qiuju; Zou, Haiming; Zhang, Kaijiong; Li, Yuping; Wang, Zuo; Deng, Yao; Meng, Fanping*; Ying, Binwu*; Yang, Mu*; Wang, Dongsheng*Clinica Chimica Acta, 2023, 541: 117244.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Chemistry
发表日期
2022-07-03
卷期
第 68 卷, 第 7 期
页码
953-962
DOI
10.1093/clinchem/hvac032
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
National Key R&D Program of China [2020YFC1316905]; National Natural Science Foundation of China [81872700, 82073625]; Planned Science and Technology Project of Guangdong Province [2019B020230002]; Heath&Medical Collaborate Innovation Project of Guangzhou City, China [201803040003]; Sun Yat-Sen University Clinical Research 5010 Program [2013012]; Intramural Research Program of National Cancer Institute (NCI), USA

作者

  • C

    Chen, Geng-Hang (第一作者)

    sun yat sen univ · 2 · guangdong prov hosp · guangzhou univ chinese med

  • L

    Liu, Zhiwei

查看全部 20 位作者收起作者
  • Y

    Yu, Kelly J.

  • C

    Coghill, Anna E.

  • C

    Chen, Xiao-Xia

    sun yat sen univ

  • X

    Xie, Shang-Hang

    sun yat sen univ

  • L

    Lin, Dong-Feng

    sun yat sen univ

  • H

    Huang, Qi-Hong

  • L

    Lu, Yu-Qiang

  • L

    Ling, Wei

  • L

    Lin, Chu-Yang

    sun yat sen univ

  • L

    Lu, Zi-Jian

    sun yat sen univ

  • F

    Fan, Yu-Ying

    sun yat sen univ

  • T

    Tang, Lin-Quan

    sun yat sen univ

  • S

    Sampson, Joshua N.

  • L

    Li, Hui

    sun yat sen univ

  • K

    King, Ann D.

    chinese univ hong kong

  • M

    Middeldorp, Jaap M.

  • H

    Hildesheim, Allan (通讯)

    6

  • C

    Cao, Su-Mei (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417